Treatment patterns following first-line pertuzumab plus trastuzumab in patients with HER2+metastatic breast cancer in the United States.

被引：1
|
作者：
Mehta, Sandhya
Pavilack, Melissa
Xie, Jipan
Ionescu-Ittu, Raluca
Nie, Xiaoyu
Lei, Yin
Kwong, Jackie
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] AstraZeneca US, Hlth Econ & Outcomes Res, Gaithersburg, MD USA
[3] Anal Grp Inc, Los Angeles, CA USA
[4] Grp Anal Ltee, Montreal, PQ, Canada
[5] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e18746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18746
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
    McCormack, Paul L.
    DRUGS, 2013, 73 (13) : 1491 - 1502
  • [32] Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
    Paul L. McCormack
    Drugs, 2013, 73 : 1491 - 1502
  • [33] Treatment patterns and outcomes of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment of metastatic HER-2 positive breast cancer : Comparison of Czech clinical registry and CLEOPATRA trial data
    Studentova, Hana
    Petrakova, Katarina
    Tesarova, Petra
    Buchler, Tomas
    Chloupkova, Renata
    Hejduk, Karel
    Melichar, Bohuslav
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Survival of patients with HER2+metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER
    Rugo, H.
    Kaufman, P.
    Tan-Chiu, E.
    Ulcickas, Yood M.
    Paik, S.
    Yardley, D.
    Brufsky, A.
    Mayer, M.
    Birkner, M.
    Wang, L.
    Brammer, M.
    Tripathy, D.
    CANCER RESEARCH, 2009, 69 (02) : 245S - 245S
  • [35] Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
    Moriwaki, Kensuke
    Uechi, Saki
    Fujiwara, Takaaki
    Hagino, Yu
    Shimozuma, Kojiro
    PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 437 - 447
  • [36] Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
    Kensuke Moriwaki
    Saki Uechi
    Takaaki Fujiwara
    Yu Hagino
    Kojiro Shimozuma
    PharmacoEconomics - Open, 2021, 5 : 437 - 447
  • [37] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Yu, Anthony F.
    Manrique, Carlos
    Pun, Shawn
    Liu, Jennifer E.
    Mara, Elton
    Fleisher, Amartin
    Patil, Sujata
    Jones, Lee W.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2016, 21 (04): : 418 - 424
  • [38] Budget impact of introducing neratinib for third-line treatment of HER2+metastatic breast cancer in the United States
    Anderson, Seri A. L.
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Lalla, Deepa
    Brufsky, Adam
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer
    Kim, Jin-Soo
    Han, Hye-Suk
    Im, Seock-Ah
    Oh, Do-Youn
    Han, Won-Shik
    Lee, Se-Hoon
    Kim, Dong-Wan
    Kim, Tae-You
    Noh, Dong-Young
    Bang, Yung-Jue
    ANNALS OF ONCOLOGY, 2006, 17 : 85 - 85
  • [40] Taxane versus vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with metastatic HER2-positive breast cancer - A retrospective two-center study
    Reinhorn, Daniel Jack
    Kuchuk, Irina
    Prus, Judit
    Sarfaty, Michal
    Goldvaser, Hadar
    Rotem, Ofer
    Hendler, Daniel
    Zoref, Dalia
    Neiman, Victoria
    Shohat, Tzipora
    Ulitsky, Olga
    Yust-Katz, Shlomit
    Nisenbaum, Bella
    Gottfried, Maya
    Yerushalmi, Rinat
    CANCER RESEARCH, 2020, 80 (04)
12345